Article
The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study.
Targeted oncology - 1 Jun 2018
Knapen Lotte M, Koornstra Rutger H T, Driessen Johanna H M, van Vlijmen Bas, Croes Sander, Schalkwijk Stein, Colbers Angela, Gerritsen Winald R, Burger David M, de Vries Frank, van Erp Nielka P
Abstract excerpt
BACKGROUND: The impact of dose and simultaneous use of acid-reducing agents (ARAs) on the effectiveness of vemurafenib is unknown. OBJECTIVES: To determine the association between progression of metastatic BRAF V600 mutated melanoma and (1) dose reductions of vemurafenib and (2) simultaneous use of vemurafenib and ARAs. PATIENT AND METHODS: A retrospective cohort study of 112 first-line vemurafenib users for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.